drug
ondansetron ODT
Marketedupdated 3mo agoby Ipca Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval382 co-mentions · 163 sources
- drugONDANSETRON250 co-mentions · 166 sources
- drugondansetron hydrochloride ODT250 co-mentions · 166 sources
- drugondansetron hydrochloride CR208 co-mentions · 124 sources
- drugONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE208 co-mentions · 124 sources
- drugONDANSETRON HYDROCHLORIDE208 co-mentions · 124 sources
- tagSmall Molecule92 co-mentions · 92 sources
- companyAurobindo Pharma Ltd29 co-mentions · 29 sources
all catalysts(24)
approval · 23
Aug 13, 2007
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Apr 12, 2010
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Oct 29, 2010
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Dec 8, 2010
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Mar 31, 2011
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Oct 18, 2011
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Feb 16, 2012
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Feb 16, 2012
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Dec 10, 2014
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Dec 10, 2014
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Dec 21, 2014
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Dec 21, 2014
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Mar 24, 2017
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Mar 27, 2017
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Mar 27, 2017
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Mar 7, 2018
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
May 14, 2018
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Jan 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Jan 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
May 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
May 31, 2024
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Nov 17, 2025
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Nov 24, 2025
approval
ONDANSETRON — FDA approval
ondansetron ODT
→
Trials studying ondansetron ODT
- phase2Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase1Phase I PK and Safety Study of Ondansetron Inhalation Powder
- phase3A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
- phase1A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
- phase4Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
- phase1Buprenorphine-Fentanyl Interaction Study
- phase2A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 23, 2029
~3.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 13, 2030formulationUS 90955773.9y
- Jul 13, 2030formulationUS 90955773.9y
- Nov 23, 2029formulationUS 85808303.2y
- Nov 23, 2029formulationUS 85808303.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that